Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Has results × Chalazion × Clear all

Phase

Phase NA 2 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 39 Neoplasms 31 Carcinoma, Non-Small-Cell Lung 23 Prostatic Neoplasms 22 Polycystic Ovary Syndrome 14 Pain 14 Leukemia 12 Keratosis, Actinic 12 Colorectal Neoplasms 10 Carcinoma, Hepatocellular 10 Uterine Cervical Neoplasms 9 Pancreatic Neoplasms 9 Lung Neoplasms 9 Leiomyoma 9 Carcinoma, Renal Cell 9 Brain Neoplasms 9 Ovarian Neoplasms 7 Neoplasm Metastasis 7 Melanoma 7 Lymphoma, Follicular 7 Kidney Neoplasms 7 Head and Neck Neoplasms 7 Arthritis, Rheumatoid 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Neuroendocrine Tumors 6 Lymphoma 6 Liver Neoplasms 6 Leukemia, Myeloid, Acute 6 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6 Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

Loteprednol Etabonate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00420628 2011-10-07

Pediatric Zylet Safety and Efficacy Study

Bausch & Lomb Incorporated

Phase 4 Completed

108 enrolled 11 charts

Hordeolum, Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡